Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Chris_Cargill
|
| gptkbp:collaboratesWith |
gptkb:Pfizer
gptkb:Takeda gptkb:AstraZeneca gptkb:Genentech gptkb:Neurocrine_Biosciences |
| gptkbp:focusesOn |
gptkb:G_protein-coupled_receptors_(GPCRs)
drug discovery |
| gptkbp:founded |
1990
|
| gptkbp:headquartersLocation |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sosei Heptares
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:notableProduct |
gptkb:HTL9936
HTL0018318 HTL0022562 HTL0030310 |
| gptkbp:officeLocation |
gptkb:Cambridge,_United_Kingdom
gptkb:Tokyo,_Japan |
| gptkbp:parentCompany |
gptkb:Sosei_Group_Corporation
|
| gptkbp:specializesIn |
structure-based drug design
|
| gptkbp:subsidiary |
gptkb:Heptares_Therapeutics
|
| gptkbp:tradedOn |
TSE: 4565
|
| gptkbp:website |
https://soseiheptares.com/
|
| gptkbp:bfsParent |
gptkb:Takeda
|
| gptkbp:bfsLayer |
6
|